WO2016092560A3 - Dual release bilayer tablets comprising metformin - Google Patents

Dual release bilayer tablets comprising metformin Download PDF

Info

Publication number
WO2016092560A3
WO2016092560A3 PCT/IN2015/000445 IN2015000445W WO2016092560A3 WO 2016092560 A3 WO2016092560 A3 WO 2016092560A3 IN 2015000445 W IN2015000445 W IN 2015000445W WO 2016092560 A3 WO2016092560 A3 WO 2016092560A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
dual release
release bilayer
bilayer tablets
formulation
Prior art date
Application number
PCT/IN2015/000445
Other languages
French (fr)
Other versions
WO2016092560A2 (en
Inventor
Amit Bakshi
Original Assignee
Eris Lifesciences Pvt Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eris Lifesciences Pvt Ltd. filed Critical Eris Lifesciences Pvt Ltd.
Publication of WO2016092560A2 publication Critical patent/WO2016092560A2/en
Publication of WO2016092560A3 publication Critical patent/WO2016092560A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses dual release bilayer pharmaceutical formulation in unit dosage form comprising metformin or its acid addition salt. The formulation has an advantage of achieving the minimum effective concentration (MEC) rapidly along with maintaining therapeutic plasma concentration in effective range for several hours, thus controlling blood glucose throughout the length of time.
PCT/IN2015/000445 2014-12-09 2015-12-09 Dual release bilayer tablets comprising metformin WO2016092560A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3942MU2014 2014-12-09
IN3942/MUM/2014 2014-12-09

Publications (2)

Publication Number Publication Date
WO2016092560A2 WO2016092560A2 (en) 2016-06-16
WO2016092560A3 true WO2016092560A3 (en) 2016-08-18

Family

ID=56108317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000445 WO2016092560A2 (en) 2014-12-09 2015-12-09 Dual release bilayer tablets comprising metformin

Country Status (1)

Country Link
WO (1) WO2016092560A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2680293B1 (en) * 2017-02-22 2019-08-22 Belac Invest S L Pharmaceutical composition comprising 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt thereof in the form of individualized delivery units and corresponding manufacturing process

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060256A2 (en) * 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Bilayer tablet formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011060256A2 (en) * 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Bilayer tablet formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CH . KUMAR ANIL ET AL.: "Int J Pharm Bio Sci", FORMULATION AND EVALUATION OF SUSTAINED RELEASE BILAYER TABLETS OF METFORMIN HCL AND GLIMEPIRIDE, vol. 3, no. 4, October 2013 (2013-10-01) - December 2013 (2013-12-01), pages 1 - 2, XP055310296 *

Also Published As

Publication number Publication date
WO2016092560A2 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
MY176235A (en) Compounds that inhibit mcl-1 protein
WO2015077503A8 (en) Autotaxin inhibitor compounds
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
EA201700019A1 (en) HIGHLY PURE ORIENTATION AND METHOD FOR ITS OBTAINING
DK3604304T3 (en) PYRROLO-PYRIDINE DERIVATIVE COMPOUND, PROCESS FOR MANUFACTURE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING IT AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF PROTEIN KINASE-RELATED DISEASES
EP3138834A4 (en) Cyclohexene derivative, preparation method therefor, and pharmaceutical composition for preventing or treating metabolic diseases, containing same as active ingredient
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
MX2015014958A (en) Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same.
PH12016502568B1 (en) Novel heterocyclic compound
EP3391908A4 (en) Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
MA42611A (en) COMBINED TREATMENT INCLUDING THE ADMINISTRATION OF 2-AMINO-3,5,5-TRIFLUORO-3,4,5,6-TETRAHYDROPYRIDINES
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
IL280389A (en) A substituted derivative of cholanoic acid, a pharmaceutical composition comprising it and the substituted derivative for use in treatment
EP3530654A4 (en) Quinolinyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition thereof, and use thereof
WO2015001541A3 (en) Pharmaceutical film composition
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
WO2016057660A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016020408A3 (en) Compounds for preventing ototoxicity
WO2016092560A3 (en) Dual release bilayer tablets comprising metformin
HK1259373A1 (en) Pharmaceutical formulations for the treatment of diabetes
CY1120192T1 (en) UNIONS TO ENHANCE KNOWLEDGE FUNCTIONING
WO2016073493A3 (en) Antifibrinolytic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15867225

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15867225

Country of ref document: EP

Kind code of ref document: A2